New Monoclonal Antibodies & Immunotherapies treatments in trials

Pembrolizumab, Nivolumab, Adalimumab — targeted oncology & autoimmune biologics. Track the treatments still in clinical testing and see which are closest to an FDA decision.

1,557Closest to approval (Phase 3)
5,809Mid-stage (Phase 2)
3,720Early stage (Phase 1)
18,713Total recruiting
In one line

18,713 monoclonal antibodies & immunotherapies trials are recruiting right now, 1,557 of them in Phase 3 — the stage immediately before an FDA decision.

Recruiting now

Twelve of the currently recruiting studies. Open one for a plain-English summary of who it is for and what it involves.

NCT07427186NARecruitingMonitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy of Immunotherapy in Patients With Early Stage CancerSponsorInstitut Claudius RegaudEnrolling600Summary NCT06107686Phase 2RecruitingA Study of YL202 in Selected Patients With Advanced Solid TumorsSponsorMediLink Therapeutics (Suzhou) Co., Ltd.Enrolling200Summary NCT06053086NARecruitingSAHARA-04 : Adaptive Radiotherapy in Hypersensitive Patients and High Locoregional Risk Breast Cancer With ETHOS TechnologySponsorInstitut du Cancer de Montpellier - Val d'AurelleEnrolling500Summary NCT05761470Phase 2RecruitingNeoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene MutationSponsorYing LinEnrolling66Summary NCT06394869NARecruitingStudy to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.SponsorPacific Edge LimitedEnrolling1,000Summary NCT06866483RecruitingValidation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated AssessmentSponsorZS AssociatesEnrolling1,000Summary NCT07144254Phase 1RecruitingTegavivint With Gemcitabine in Patients With Relapsed or Refractory OsteosarcomaSponsorEmory UniversityEnrolling24Summary NCT07589205Phase 1RecruitingStudy of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid TumorsSponsorInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.Enrolling493Summary NCT03719105EARLY_Phase 1RecruitingChemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/LymphomaSponsorNew York Medical CollegeEnrolling40Summary NCT04473794RecruitingDiagnostic Strategies, Risk Assessment and Progression of Pancreatic CystsSponsorJohns Hopkins UniversityEnrolling5,000Summary NCT07464951Phase 1RecruitingCART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid LeukemiaSponsorStephan Grupp MD PhDEnrolling30Summary NCT05625529RecruitingExoLuminate Study for Early Detection of Pancreatic CancerSponsorBiological DynamicsEnrolling1,000Summary

View all 18,713 on ClinicalTrials.gov

Already approved for this area

Monoclonal Antibodies / Immunotherapies

Keytruda, Opdivo, Humira, Dupixent — approved products with their NDC records and billing codes.

Open the class

Every NDC in this class

The FDA registry filtered to monoclonal antibodies / immunotherapies, with packaging and 11-digit billing conversions.

Search the directory

Loading the trial explorer…